Comparison |
| Alternate Manufacturer Number |
1925965 | 2017226 | 1904341 | | 3655321 |
| Container Type |
Prefilled Syringe | Single-Dose Vial | Flexible Bag | Single-Dose Vial | Single-Dose Vial |
| Country of Origin |
Singapore | India | Switzerland | Singapore | Unknown |
| Generic Drug Code |
28656 | 25026 | 34228 | 29261 | 25026 |
| Generic Drug Name |
Denosumab, Preservative Free | Zoledronic Acid / Mannitol-Water | Zoledronic Acid / Mannitol-Water | Denosumab, Preservative Free | Zoledronic Acid |
| NDC Number |
55513071001 | 55111068852 | 25021083082 | 55513073001 | 67457061910 |
| Product Dating |
McKesson Acceptable Dating: we will ship >= 180 days | McKesson Acceptable Dating: we will ship >= 90 days | McKesson Acceptable Dating: we will ship >= 90 days | McKesson Acceptable Dating: we will ship >= 180 days | McKesson Acceptable Dating: we will ship >= 90 days |
| Storage Requirements |
Requires Refrigeration | | | Requires Refrigeration | |
| Strength |
60 mg / mL | 5 mg / 100 mL | 5 mg / 100 mL | 120 mg | 5 mg / 100 mL |
| Type |
Subcutaneous | Intravenous | Intravenous | Subcutaneous | Intravenous |
| UNSPSC Code |
51182428 | 51182415 | 51182415 | 51182428 | 51182415 |
| User |
Adult | | | | |
| Volume |
1 mL | 100 mL | 100 mL | 1.7 mL | 100 mL |
| Application |
Bone Resorption Inhibitor | Bone Resorption Inhibitor | Bone Resorption Inhibitor | Bone Resorption Inhibitor | Bone Resorption Inhibitor |
| Dosage Form |
Injection | Injection | Injection | Injection | Injection |
| Features and Benefits |
- Prolia® (denosumab) is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy
- Prolia is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
- Prolia is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer
- All patients should receive calcium 1000 mg daily and at least 400 IU vitamin D daily
- Pre-existing hypocalcemia must be corrected prior to initiating Prolia®
- Administer 60 mg every 6 months as a subcutaneous injection in the upper arm, upper thigh, or abdomen
- Each 1 mL single-use prefilled syringe of Prolia contains 60 mg denosumab (60 mg/mL solution), 4.7% sorbitol, 17 mM acetate, 0.01% polysorbate 20, Water for Injection (USP), and sodium hydroxide to a pH of 5.2
- Store Prolia in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton
- Protect Prolia from direct light and heat
|
- Ready-to-use formulation
- Zoledronic acid injection is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy, multiple myeloma and bone metastases from solid tumors
- The zoledronic acid injection infusion time must not be less than 15 minutes given over a constant infusion rate
- Zoledronic acid injection must not be mixed with calcium or other divalent cation-containing infusion solutions, such as Lactated Ringer’s solution, and should be administered as a single intravenous solution in a line separate from all other drugs
- Infusion bottle with built-in plastic hanger
- One bottle with 100 mL solution contains 5.330 mg of zoledronic acid monohydrate, equivalent to 5 mg zoledronic acid on an anhydrous basis
- Inactive Ingredients: 4950 mg of mannitol, USP; and 30 mg of sodium citrate, USP
|
|
|
|
